Liquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma

Biomedical Chromatography

Volumn 27, Issue 2, 2013, Pages 172-178

  Burugula, Laxminarayana ^a   Pilli, Nageswara Rao ^a   Makula, Ajitha ^a   Lodagala, Durga Srinivas ^b   Kandhagatla, Rajnarayana ^c  

^a Glukem Pharmaceuticals Pvt Ltd   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^c Bristl Laboratories Ltd   (United Kingdom)

Author keywords

Liquid chromatography tandem mass spectrometry; Liquid liquid extraction (LLE); Method validation; Pharmacokinetic studies; Rilpivirine in human plasma

Indexed keywords

BIOMOLECULES; LIQUID CHROMATOGRAPHY; PHARMACOKINETICS; PLASMA (HUMAN); SOLVENT EXTRACTION;

HUMAN PLASMAS; INTERNAL STANDARDS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; LIQUID-LIQUID EXTRACTION; METHOD VALIDATIONS; NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS; PHARMACOKINETIC STUDIES; RILPIVIRINE IN HUMAN PLASMA;

MASS SPECTROMETRY;

ACETONITRILE; FORMIC ACID; NEVIRAPINE; RILPIVIRINE;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FLOW RATE; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; PLASMA; STANDARD; TANDEM MASS SPECTROMETRY;

EID: 84872003153     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2765     Document Type: Article

References (10)

1. Carpenter CCJ, Fischl MA and Hammer SM. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA Panel. Journal of the American Medical Association 1997; 277: 962-969.
2. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S and Boven K. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378: 229-237.
3. Else L, Watson V, Tjia J, Hughes A, Siccardi M, Khoo S and Back D. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. Journal of Chromatography B 2010; 878: 1455-1465.
4. FDA. Label for rilpivirine tablets, May 2011. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf (accessed on March 23, 2012).
5. Ford N, Lee J, Andrieux-Meyer I and Calmy A. Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV/AIDS - Research and Palliative Care 2011; 3: 35-44.
6. Goebel F, Yakovlev A, Pozniak AL, Vinogradova E, Boogaerts G, Hoetelmans R, de Bethune MP, Peeters M and Woodfall B. Short-term antiviral activity of TMC278 - a novel NNRTI - in treatment-naive HIV-1-infected subjects. AIDS 2006; 20: 1721-1726.
7. Hirschel B and Perneger T. No patient left behind - better treatments for resistant HIV infection. Lancet 2007; 370: 3-5.
8. Molina J-M, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S and Boven K. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomized double-blind active-controlled trial. Lancet 2011; 378: 238-246.
9. Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 2010; 24: 55-65.
10. US DHHS, FDA and CDER. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, 2001. Available at: http://www/fda.gov/cder/guidance/index.htm.